TITLE

OCTOPLUS/LUMC BEGIN TRIALS FOR MIDDLE EAR INFECTION DRUG

PUB. DATE
March 2004
SOURCE
Worldwide Biotech;Mar2004, Vol. 16 Issue 3, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the partnership between Octoplus and Leiden University Medical Centre on conducting patient trials for a drug against chronic middle ear infection.
ACCESSION #
12391243

 

Related Articles

  • OCTOPLUS\BIOLEX DEVELOPING LOCTERON.  // Worldwide Biotech;Apr2005, Vol. 17 Issue 4, p1 

    Focuses on the deal between drug delivery and development company OctoPlus and protein therapeutics firm Biolex Inc. to co-develop a controlled release formulation of recombinant human alfa interferon called Locteron. Characteristics of the drug; Terms of the deal; Background information on the...

  • European Association for the Study of the Liver.  // BioWorld Today;4/16/2010, Vol. 21 Issue 73, p6 

    The article reports that Locteron from Biolex Therapeutics Inc. and OctoPlus NV, dosed every other week, reduced viral load and flu-like adverse events.

  • OctoPlus Shares Surge After Dr. Reddy's $36M Buyout Bid. Sheridan, Cormac // BioWorld International;10/24/2012, Vol. 17 Issue 43, p4 

    This article reports on the decision of Dutch drug delivery specialist OctoPlus NV to agree to a 27.4 million euros (35.8 million U.S. dollars) cash offer from Indian generics firm Dr. Reddy's Laboratories Ltd. The offer represents a 30 percent premium over the company's closing share price of...

  • Other News To Note.  // BioWorld Today;9/21/2010, Vol. 21 Issue 182, p4 

    This section offers news briefs in the pharmaceutical industry. Japan has approved the Synvisc drug from Genzyme Corp. for osteoarthritis of the knee. A feasibility agreement has been signed by OctoPlus NV with a U.S.-based pharmaceutical company for the use of its controlled-release technology....

  • Advances in Single-Shot Vaccine Development. Kremer, Bas; Roukema, Rianne; de Leede, Leo // BioPharm International;Jan2009 Supplement, p28 

    The article describes the manufacture of a prototype single-shot vaccine that combines a prime and booster dose in one injection based on the example of hepatitis B vaccination. Accordingly, the vaccine uses OctoPlus NV's OctoVAX microsphere technology, which has been proven to be well-tolerated...

  • Controlled release drug delivery system.  // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p40 

    The article reports that Dutch drug delivery and development firm, OctoPlus, has been successful in the clinical trials it has conducted with partner Biolex Therapeutics. The two companies are trying to develop a controlled release treatment for hepatitis C by applying OctoPlus' PolyActive...

  • Financings Roundup.  // BioWorld Today;12/21/2010, Vol. 21 Issue 245, p3 

    This article reports that OctoPlus NV has successfully raised four million euros via a private placement deal with new and existing investors.

  • Financings Roundup.  // BioWorld Today;7/14/2008, Vol. 19 Issue 135, p10 

    This article reports that OctoPlus NV of the Netherlands will receive an additional €2 million under the terms of its bridge financing that started in March 2008. The said payment was made by Biolex Therapeutics Inc., the company's co-development partner in Locerton. This amount will allow...

  • Locteron Developer Biolex Liquidates; $35M in the Red. Shaffer, Catherine // BioWorld Today;7/11/2012, Vol. 23 Issue 133, p1 

    The article details the announcement made by OctoPlus N.V., provider of pharmaceutical services, that its partner Biolex Therapeutics Inc., has already filed bankruptcy liquidation. Biolex filed a voluntary petition for liquidation under Chapter 7 in the Bankruptcy Court for the Middle District...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics